EPILEPSY DRUGS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Epilepsy Drugs Market, By Type of Epilepsy (Focal Epilepsy, Generalized Epilepsy, Reflex Epilepsy, and Others (Progressive Myoclonic Epilepsy, etc.)), By Drugs (1st Generation, 2nd Generation, and 3rd Generation), By Route of Administration (Oral, Injectable, and Others (Nasal, etc.)), By Age Group (Pediatric, Adults, and Geriatric), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

On June 28, 2024, Angelini Pharma, a pharmaceutical company, in partnership with Wazoku, a health technology copany, launched a new crowdsourcing campaign to identify new innovative Drug Delivery Systems (DDS) and treatments approaches to significantly improve the lives of people with epilepsy, especially elderly and pediatric patients
On May 13, 2024, Eisai Co., Ltd., a pharmaceutical company, announced that it had received approval in China from National Medical Products Administration for an additional indication for its antiepileptic drug, Fycompa (generic name: perampanel hydrate). This approval allows Fycompa to be used as an adjunctive treatment for primary generalized tonic-clonic seizures in patients with epilepsy aged 12 years and older.
On January 10, 2024, Akumentis Healthcare, a pharmaceutical company, announced that it had launched Clasepi, a Drugs Controller General of India-approved prescription cannabidiol (CBD) specifically designed for treating epilepsy. This innovative medication targets seizures associated with Lennox-Gastaut Syndrome, Dravet Syndrome, and Tuberous Sclerosis Complex in patients aged one year and older.